Effects of sotagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease stages 3 and 4.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 1010, doi. 10.1111/dom.16079
- By:
- Publication type:
- Article
Works by CARROLL, AMY K.
Results: 5
1
2
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2632, doi. 10.1111/dom.14513
- By:
- Publication type:
- Article
3
136-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Moderate Renal Impairment.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-136-LB
- By:
- Publication type:
- Article
4
135-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Severe Renal Impairment.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-135-LB
- By:
- Publication type:
- Article
5
1102-P: Impact of Treatment with Sotagliflozin on the Incidence of Severe Hypoglycemia in Patients with T1D.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-1102-P
- By:
- Publication type:
- Article